Literature DB >> 33052055

Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.

Sam Keeping1, Yingxin Xu2, Chieh-I Chen2, Shannon Cope1, Ali Mojebi1, Andreas Kuznik2, Gerasimos Konidaris3, Dieter Ayers1, Medha Sasane4, Rachel Allen3, Thi-Minh-Thao Huynh5, Evan Popoff1, Morganna Freeman6, Michael L Andria2, Matthew G Fury2, Kanwarjit Singh4, Eggert Stockfleth7, Amarnath Challapalli8, Chrysalyne D Schmults9.   

Abstract

Aim: To estimate the comparative efficacy of cemiplimab, a programmed cell death protein 1 inhibitor, versus EGFR inhibitors, pembrolizumab and platinum-based chemotherapy in terms of overall survival (OS) and progression-free survival. Patients & methods: We performed an indirect treatment comparison of cemiplimab and other available systemic therapies for patients with advanced cutaneous squamous cell carcinoma.
Results: Cemiplimab was associated with benefits in OS (hazard ratios range: 0.07-0.52) and progression-free survival (hazard ratios range: 0.30-0.67) versus EGFR inhibitors and pembrolizumab (data from KEYNOTE-629). Cemiplimab was more efficacious versus platinum-based chemotherapy in terms of OS.
Conclusion: Cemiplimab may offer improvements in survival for advanced cutaneous squamous cell carcinoma patients compared with existing systemic therapies.

Entities:  

Keywords:  cemiplimab; cutaneous squamous cell carcinoma; immuno-oncology; indirect treatment comparison; nonmelanoma skin cancer

Year:  2020        PMID： 33052055     DOI： 10.2217/fon-2020-0823

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  12 in total

Review 1.  Lower lip basal cell and squamous cell carcinomas: a reappraisal of the similarities and differences in clinical presentation and management.

Authors:  Jacqueline R Hwang; Amor Khachemoune
Journal:  Arch Dermatol Res       Date:  2022-03-21       Impact factor: 3.017

Review 2.  Immune Checkpoint Inhibitors in Cancer Therapy.

Authors:  Yavar Shiravand; Faezeh Khodadadi; Seyyed Mohammad Amin Kashani; Seyed Reza Hosseini-Fard; Shadi Hosseini; Habib Sadeghirad; Rahul Ladwa; Ken O'Byrne; Arutha Kulasinghe
Journal:  Curr Oncol       Date:  2022-04-24       Impact factor: 3.109

Review 3.  Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: The Current and Future Role of Radiation Therapy in the Era of Immunotherapy.

Authors:  Gianluca Ferini; Paolo Palmisciano; Stefano Forte; Anna Viola; Emanuele Martorana; Silvana Parisi; Vito Valenti; Corrado Fichera; Giuseppe Emmanuele Umana; Stefano Pergolizzi
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

Review 4.  Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.

Authors:  Somayeh Vafaei; Angelina O Zekiy; Ramadhan Ado Khanamir; Burhan Abdullah Zaman; Arman Ghayourvahdat; Hannaneh Azimizonuzi; Majid Zamani
Journal:  Cancer Cell Int       Date:  2022-01-03       Impact factor: 5.722

Review 5.  Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma.

Authors:  Matthew L Hedberg; Corbett T Berry; Ata S Moshiri; Yan Xiang; Christopher J Yeh; Cem Attilasoy; Brian C Capell; John T Seykora
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

6.  Anti-PD-1 for the treatment of advanced cutaneous squamous cell carcinoma in elderly patients: a French multicenter retrospective survey.

Authors:  Quentin Samaran; Romain Samaran; Ernestine Ferreira; Naeda Haddad; Antoine Fottorino; Hervé Maillard; Brigitte Dreno; Nicolas Meyer; David Azria; Eve Maubec; Caroline Gaudy-Marqueste; Nicolas Molinari; Pierre-Emmanuel Stoebner; Olivier Dereure
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-12       Impact factor: 4.322

7.  A network pharmacology-based exploration of the active compounds and potential drug targets of Si-Jun-Zi decoction in the treatment of cutaneous squamous cell carcinoma.

Authors:  Si Qin; Lan-Yue Zhang; Hao-Bin Zhang; Si-Man Shi; Xin Zhou; Zhen-Yu Lu; Yi-Xue Duan; Wen-Bin Huang; Ju Wen
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

Review 8.  Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.

Authors:  Alexander Malogolovkin; Nizami Gasanov; Alexander Egorov; Marianna Weener; Roman Ivanov; Alexander Karabelsky
Journal:  Viruses       Date:  2021-06-29       Impact factor: 5.048

9.  Identification of CDK1 as a candidate marker in cutaneous squamous cell carcinoma by integrated bioinformatics analysis.

Authors:  Si Qin; Yu Yang; Hao-Bin Zhang; Xiao-Huan Zheng; Hua-Run Li; Ju Wen
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

10.  Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment.

Authors:  Elisabetta Gambale; Sara Fancelli; Enrico Caliman; Maria Cristina Petrella; Laura Doni; Serena Pillozzi; Lorenzo Antonuzzo
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.